Osteosarcoma

NCI Definition: A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs. [1]

Clinical Trials

View Clinical Trials for Osteosarcoma

There are 47 clinical trials for osteosarcoma, of which 42 are open and 5 are completed or closed. Of the trials that contain osteosarcoma as an inclusion criterion, 2 are early phase 1 (2 open), 13 are phase 1 (10 open), 8 are phase 1/phase 2 (8 open), 23 are phase 2 (21 open), and 1 is no phase specified (1 open).

CDK4, ATM, and ATR are the most frequent gene inclusion criteria for osteosarcoma clinical trials [3].

Trials Investigating Osteosarcoma by Gene and Recruiting Status

Cyclophosphamide, gemcitabine, and nivolumab are the most common interventions in osteosarcoma clinical trials.

Drugs Being Investigated in Osteosarcoma Trials by Recruiting Status

Significant Genes in Osteosarcoma

AKT1 +

AKT1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 +

AKT2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 +

AKT3 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ARID1A +

ARID1A is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM +

ATM is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ATR +

ATR is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ATRX +

ATRX is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AXL +

AXL is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 +

BARD1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA1 +

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 +

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 +

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CCND1 +

CCND1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND2 +

CCND2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 +

CCND3 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 +

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 +

CDK12 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CDK4 +

CDK4 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 +

CDK6 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A +

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 +

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CHEK2 +

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CRKL +

CRKL is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EWSR1 +

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA +

FANCA is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCB +

FANCB is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCB status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCC +

FANCC is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCC status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCD2 +

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCD2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCE +

FANCE is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCE status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCF +

FANCF is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCF status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCG +

FANCG is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCG status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCI +

FANCI is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCI status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCL +

FANCL is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCL status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCM +

FANCM is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCM status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FBXW7 +

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FUS +

FUS is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 +

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MCPH1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MET +

MET is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A +

MRE11A is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MRE11A status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MTOR +

MTOR is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYCN +

MYCN is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NBN +

NBN is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 +

PALB2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA +

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG +

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 +

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 +

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN +

PTEN is an inclusion eligibility criterion in 3 clinical trials for osteosarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD50 +

RAD50 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51 +

RAD51 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51B +

RAD51B is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C +

RAD51C is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D +

RAD51D is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L +

RAD54L is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR +

RICTOR is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR +

RPTOR is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SDHA +

SDHA is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHA status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHAF2 +

SDHAF2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHAF2 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHB +

SDHB is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHC +

SDHC is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHC status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHD +

SDHD is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHD status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 +

SLX4 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain SLX4 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TSC1 +

TSC1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 +

TSC2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

Osteogenic Sarcoma, OSTEOSARCOMA, MALIGNANT

Parent(s)

Sarcoma

Children

Extraskeletal Osteosarcoma, Localized Osteosarcoma, Bone Osteosarcoma, and Childhood Osteosarcoma

OncoTree Name

Osteosarcoma

OncoTree Code

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Osteosarcoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Osteosarcoma

Disease Details

References

About

Molecular Medicine

Content Types